Charles River Laboratories Intl. Inc (CRL) Given Consensus Rating of “Buy” by Brokerages

Charles River Laboratories Intl. Inc (NYSE:CRL) has earned a consensus recommendation of “Buy” from the nineteen research firms that are covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $133.07.

A number of research analysts recently issued reports on CRL shares. Raymond James raised their price target on Charles River Laboratories Intl. from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 8th. Robert W. Baird raised their price target on Charles River Laboratories Intl. from $133.00 to $141.00 and gave the stock an “outperform” rating in a research note on Monday, September 17th. Royal Bank of Canada set a $147.00 price target on Charles River Laboratories Intl. and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Morgan Stanley raised their price target on Charles River Laboratories Intl. from $112.00 to $136.00 and gave the stock an “equal weight” rating in a research note on Monday, December 3rd. Finally, ValuEngine downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Wednesday, October 24th.

Shares of CRL traded down $0.38 during mid-day trading on Friday, reaching $119.21. The company’s stock had a trading volume of 265,994 shares, compared to its average volume of 489,624. Charles River Laboratories Intl. has a 12-month low of $96.70 and a 12-month high of $139.72. The company has a market cap of $5.67 billion, a P/E ratio of 22.62, a PEG ratio of 1.55 and a beta of 0.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.32 and a current ratio of 1.55.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 7th. The medical research company reported $1.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.38 by $0.15. The firm had revenue of $585.30 million for the quarter, compared to the consensus estimate of $567.58 million. Charles River Laboratories Intl. had a return on equity of 25.08% and a net margin of 6.39%. The firm’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.30 EPS. As a group, analysts predict that Charles River Laboratories Intl. will post 5.92 earnings per share for the current fiscal year.

In other Charles River Laboratories Intl. news, Chairman James C. Foster sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 8th. The stock was sold at an average price of $115.00, for a total transaction of $2,875,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Ross Smith sold 1,866 shares of the stock in a transaction that occurred on Monday, November 12th. The stock was sold at an average price of $134.49, for a total value of $250,958.34. Following the sale, the insider now directly owns 12,341 shares of the company’s stock, valued at $1,659,741.09. The disclosure for this sale can be found here. Insiders have sold a total of 55,639 shares of company stock valued at $7,017,794 over the last ninety days. 2.10% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of CRL. Csenge Advisory Group acquired a new stake in Charles River Laboratories Intl. during the 3rd quarter worth approximately $91,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Charles River Laboratories Intl. in the 2nd quarter valued at approximately $122,000. Brown Brothers Harriman & Co. acquired a new stake in shares of Charles River Laboratories Intl. in the 3rd quarter valued at approximately $202,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Charles River Laboratories Intl. in the 2nd quarter valued at approximately $212,000. Finally, CIBC Asset Management Inc acquired a new stake in shares of Charles River Laboratories Intl. in the 3rd quarter valued at approximately $226,000. 95.83% of the stock is owned by institutional investors.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Risk Tolerance

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit